- CEO
- Cheng Zhi Yao
- Full Time Employees
- 2,370
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Building1,Ningbo R&D Park Ningbo ZH China 315048
- IPO Date
- Apr 7, 2017
- Business
- Ningbo Menovo Pharmaceutical Co., Ltd. Ningbo Menovo Pharmaceutical Co., Ltd. (603538.SS) researches, develops, produces and sells pharmaceutical products including active pharmaceutical ingredients (APIs), intermediates and finished dosage forms; its core offerings encompass cardiovascular treatments such as Valsartan, Losartan, Perindopril, Rosuvastatin Calcium and Atorvastatin Calcium; central nervous system medications including Pregabalin and Clopidogrel; as well as products for antiviral, hypoglycemic, gastrointestinal, respiratory, antitumor, anti-infection, digestive and geriatric applications like Apixaban Tablets, Lisinopril Tablets, Co-dergocrine Mesylate Tablets and Aminophylline Tablets.
Founded in 2004 and headquartered in Ningbo City, Zhejiang Province, China, the company operates primarily in China with subsidiaries and facilities in Anhui and Zhejiang provinces, a Sino-European joint venture, provincial research institutes, and offices in India, the US and Europe; it serves domestic and international markets, particularly Europe as one of China's top exporters of characteristic APIs, and holds recognition as a top 20 CDMO enterprise in China for multiple years.
Menovo maintains a fully integrated industrial chain for R&D, production and commercialization of its products, bolstered by rigorous quality, EHS management and large-scale manufacturing capabilities that support long-term partnerships with global pharmaceutical firms; it provides CDMO services encompassing contract development, manufacturing and one-stop platforms.
In recent developments, the company suspended its high-end preparation project in July 2024 amid market shifts, centralized procurement pressures and product saturation, opting to re-evaluate investments and actively seek partners for high-end formulations while deepening research into industry trends; it completed full acquisition of the remaining 49% stake in Xuancheng Menovo Pharmaceutical Co., Ltd. in 2022 for approximately CNY 151.6 million, enhancing its preparation capabilities.